3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
4
Phase EARLY_PHASE1
1
Phase 4
1
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
26
Leukemia, Lymphocytic, Chronic, B-Cell
16
Myelodysplastic Syndromes
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, Non-Hodgkin
6
Lymphoma, Follicular
6
Leukemia
6
Multiple Myeloma
5
Lymphoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Recurrence
2
Myeloproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Graft vs Host Disease
2
Waldenstrom Macroglobulinemia
1
Venentoclax
1
Sarcoma, Synovial
1
Primary Myelofibrosis
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm, Residual
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Biphenotypic, Acute
1
Burkitt Lymphoma
1
Anemia, Refractory, with Excess of Blasts
1
Anemia
1
Interventions
osimertinib
1
obinutuzumab
1
midostaurin
1
flumatinib
1
fludarabine
1
Radiotherapy
1
Oxaliplatin
1
Mitoxantrone
1
Mercaptopurine
1
Leucovorin
1
Irinotecan
1
Gemtuzumab
1
Folfox protocol
1
Fluorouracil
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm, Residual
×
fludarabine
×
Clear all
NCT02724163
2021-10-08
Myechild01
University of Birmingham
Phase 3
Recruiting
700 enrolled